# Guardant Health, Inc.

**GH**

Nasdaq; healthcare; SIC 8071, Services-Medical Laboratories; CIK 0001576280

**B**

**second fifth of 369 graded peers in healthcare**

rank 89 of 369; percentile 23.9; sampling error 2.5 points; lower is stronger

A B C D E

**B, the elk**




| Scoreboard | |
|---|---|
| **Profitability** | B/C<br>percentile 41.0 |
| **Solvency** | C<br>percentile 42.9 |
| **Growth and financing** | B<br>percentile 35.0 |
| **Reliability** | 0.91 AUC<br>filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025 |
| **Peer failure rate** | 1.01% a year<br>Item 1.03 bankruptcies, same asset band, 2012 to 2025 |
| **Size band** | $591M to $2.67B assets<br>total assets $2.0B |
| **Standard universe** | inside<br>revenue above $1M and assets above $10M |
| **Warnings** | none triggered<br>not computable: distress |
| **Inputs computable** | 7 of 14 |
| **Graded from** | filings received through Feb 19, 2026<br>255 days before the rescan; latest periodic filing 10-Q received Jul 30, 2026 |
| **Last close** | $178.80<br>2026-10-30; market equity $24.0B; no price enters the letter |

**Share price, twelve months to the rescan**




*Split-adjusted close. Each lollipop is a rescan and carries the letter held then.*

**Letter at every rescan, 2012 to 2026**




*Sector percentile at each rescan, stronger toward the top; facts filed by each date only.*

## Business, in the company's words

*opening of Item 1 of the 10-K received Feb 19, 2026*

We are a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. We are transforming patient care by providing critical insights into what drives disease through our advanced blood and tissue tests, real-world data and AI analytics. Our tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer.

## The fourteen inputs

*lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight*


| Input | Value | Peer median | Percentile, 0 to 100 | Pct | Peers | Period end |
|---|---|---|---|---|---|---|
| **Profitability, sleeve percentile 41.0** | | | | | | |
| Gross profitability | 31.4% | 32.4% | | 48.5 | 366 | 2025-12-31 |
| Return on invested capital | not computable | 9.3% | | | | |
| *a prior annual debt, equity, and cash observation is required* | | | | | | |
| Accruals ratio | (13.2%) | (6.6%) | | 33.4 | 803 | 2025-12-31 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | |
|---|---|---|---|---|---|---|
| Gross margin stability, five years | not computable | 2.8 pts | | | | |
| *five annual gross margins are required; found 1* | | | | | | |
| **Solvency, sleeve percentile 42.9** | | | | | | |
| Twelve-month failure probability | not computable | 0.08% | | | | |
| *latest liabilities, cash plus short-term investments, book equity, and shares are required* | | | | | | |
| Altman Z double-prime | (2.57) | (0.35) | | 47.8 | 748 | 2025-12-31 |
| Net debt to EBITDA | not computable | 1.82x | | | | |
| *EBITDA must exceed $100,000* | | | | | | |
| Interest coverage | not computable | (4.51x) | | | | |
| *latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31* | | | | | | |
| Current ratio | 4.84x | 2.92x | | 38.0 | 829 | 2025-12-31 |
| **Growth and financing, sleeve percentile 35.0** | | | | | | |
| Revenue growth, three-year compound | 29.8% | 10.1% | | 22.4 | 412 | 2025-12-31 |
| Free cash flow growth, three-year compound | not computable | 10.9% | | | | |
| *current FCF must be positive and base FCF must exceed $100,000* | | | | | | |
| Reinvestment rate | not computable | 37.1% | | | | |
| *NOPAT must exceed $100,000* | | | | | | |
| Asset growth, three years | 7.7% | 2.2% | | 35.7 | 696 | 2025-12-31 |
| Net share issuance, one year | 6.3% | 2.5% | | 47.0 | 631 | 2026-02-13 |

## Among 369 peers

*healthcare; letters are fifths of this list*




*Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.*

| Rank | Company | Percentile | Letter | Warnings |
|---|---|---|---|---|
| 84 | Halozyme Therapeutics, Inc. (HALO) | 22.6 | B | |
| 85 | Lineage Cell Therapeutics, Inc. (LCTX) | 22.8 | B | |
| 86 | Puma Biotechnology, Inc. (PBYI) | 23.1 | B | fortress balance sheet |
| 87 | Warby Parker Inc. (WRBY) | 23.4 | B | |
| 88 | Sarepta Therapeutics, Inc. (SRPT) | 23.6 | B | |
| 89 | Guardant Health, Inc. (GH) | 23.9 | B | |
| 90 | Amphastar Pharmaceuticals, Inc. (AMPH) | 24.2 | B | |
| 91 | Cronos Group Inc. (CRON) | 24.5 | B | |
| 92 | 4D Molecular Therapeutics, Inc. (FDMT) | 24.7 | B | dilution, short runway |
| 93 | Pulmonx Corp. (LUNG) | 25.0 | B | fortress balance sheet |
| 94 | Mirum Pharmaceuticals, Inc. (MIRM) | 25.3 | B | |

## What the price implies

*at the 2026-10-30 close; none of these enters the grade*

| Measure | Value | Peer median | Percentile |
|---|---|---|---|
| Twelve-month price change, skipping the latest month | 91.7% | (2.2%) | 89 |
| Distance from 52-week high | (4.5%) | (28.7%) | 85 |
| EBIT to enterprise value | (1.8%) | (1.4%) | 48 |
| Free cash flow yield | (1.0%) | (1.0%) | 49 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | |
|---|---|---|---|
| Book value to price | (0.01) | 0.28 | 11 |
| Sales to price | 0.04 | 0.30 | 15 |
| Composite equity issuance, five years | 29.0% | 20.5% | 57 |
| Relative strength against the sector, log excess return | 0.48 | (0.19) | 89 |

## Diagnostics

*shown on every report; none enters the grade*

| Measure | Value |
|---|---|
| **Piotroski F-score None of 9, period end 2025-12-31** | |
| Return on assets above zero | fail |
| Operating cash flow above zero | fail |
| Return on assets improved | fail |
| Operating cash flow exceeds net income | pass |
| Long-term leverage fell | fail |
| Current ratio improved | pass |
| No new shares issued | fail |
| Gross margin improved | fail |
| Asset turnover improved | pass |
| **Cash, filings, liquidity** | |
| Cash and equivalents | $1.1B |
| Operating cash flow, four quarters | -$185.2M |
| Months of runway | 68.3 |
| Days since last periodic filing | 94 (10-Q received Jul 30, 2026) |
| Median daily dollar volume, 63 sessions | $294.3M |

## Sources

*every fact behind the inputs; each row links to its filing index on sec.gov*

| # | Concept | XBRL tag | Value | Period end | Received | Form | Accession |
|---|---|---|---|---|---|---|---|
| 1 | revenue | us-gaap:RevenueFromContractWithCustomerExcludingA... | $982.0M | 2025-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 2 | cost of revenue | us-gaap:CostOfGoodsAndServicesSold | $349.0M | 2025-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 3 | assets | us-gaap:Assets | $2.0B | 2025-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 4 | operating income | us-gaap:OperatingIncomeLoss | -$437.2M | 2025-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 5 | pretax income | us-gaap:IncomeLossFromContinuingOperationsBeforeInc... | -$417.5M | 2025-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 6 | income tax | us-gaap:IncomeTaxExpenseBenefit | -$1.3M | 2025-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 7 | total debt | us-gaap:LongTermDebt | $1.5B | 2025-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 8 | book equity | us-gaap:StockholdersEquity | -$99.3M | 2025-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 9 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $378.2M | 2025-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 10 | net income | us-gaap:NetIncomeLoss | -$416.3M | 2025-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 11 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$184.8M | 2025-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 12 | assets | us-gaap:Assets | $1.5B | 2024-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 13 | current assets | us-gaap:AssetsCurrent | $1.5B | 2025-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 14 | current liabilities | us-gaap:LiabilitiesCurrent | $302.7M | 2025-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 15 | retained earnings | us-gaap:RetainedEarningsAccumulatedDeficit | -$3.0B | 2025-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 16 | liabilities | us-gaap:Liabilities | $2.1B | 2025-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 17 | depreciation amortization | us-gaap:DepreciationDepletionAndAmortization | $39.7M | 2025-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 18 | operating income | us-gaap:OperatingIncomeLoss | -$564.7M | 2023-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 19 | interest expense | us-gaap:InterestExpense | $2.6M | 2023-12-31 | 2024-02-22 | 10-K | 24-000043 |
| 20 | revenue | us-gaap:Revenues | $739.0M | 2024-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 21 | revenue | us-gaap:Revenues | $563.9M | 2023-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 22 | revenue | us-gaap:Revenues | $449.5M | 2022-12-31 | 2025-02-20 | 10-K | 25-000044 |
| 23 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $48.3M | 2025-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 24 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$239.9M | 2024-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 25 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $35.1M | 2024-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 26 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$325.0M | 2023-12-31 | 2026-02-19 | 10-K | 26-000013 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| 27 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $20.5M | 2023-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 28 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$309.5M | 2022-12-31 | 2025-02-20 | 10-K | 25-000044 |
| 29 | capital expenditure | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment | $77.5M | 2022-12-31 | 2025-02-20 | 10-K | 25-000044 |
| 30 | current assets | us-gaap:AssetsCurrent | $1.1B | 2024-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 31 | current liabilities | us-gaap:LiabilitiesCurrent | $225.6M | 2024-12-31 | 2026-02-19 | 10-K | 26-000013 |
| 32 | assets | us-gaap:Assets | $1.8B | 2023-12-31 | 2025-02-20 | 10-K | 25-000044 |
| 33 | assets | us-gaap:Assets | $1.6B | 2022-12-31 | 2024-02-22 | 10-K | 24-000043 |
| 34 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 131,170,441 | 2026-02-13 | 2026-02-19 | 10-K | 26-000013 |
| 35 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 123,421,441 | 2025-02-14 | 2025-02-20 | 10-K | 25-000044 |

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.